Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 2/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776338 | 0.84 | MCHR1 (0.44) | MCHR1JAK2FYNMEN1KMT2A | |
| SCHEMBL16776339 | 0.82 | EPHX2 (0.43) | MCHR1JAK2MEN1KMT2A | |
| SCHEMBL16776340 | 0.81 | MCHR1 (0.40) | MCHR1JAK2MEN1KMT2A | |
| SCHEMBL20632351 | 0.81 | KDM4E (0.37) | UBE2MDCUN1D1FYNMEN1KMT2A | |
| SCHEMBL16776315 | 0.80 | MCHR1 (0.41) | MCHR1MEN1KMT2A | |
| SCHEMBL16776322 | 0.77 | NPC1 (0.44) | JAK2FYNMEN1KMT2A | |
| SCHEMBL16776367 | 0.76 | NPC1 (0.44) | FYNMEN1KMT2A | |
| SCHEMBL16776437 | 0.75 | RHOA (0.43) | FYN | |
| SCHEMBL16776446 | 0.75 | SIGMAR1 (0.36) | FYNMEN1KMT2A | |
| SCHEMBL19365414 | 0.74 | MCHR1 (0.45) | MCHR1UBE2MDCUN1D1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MCHR1 4256/4885JAK2 2392/4885JAK3 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.